Curia

336 articles about Curia

• Curia wins 2023 Frost & Sullivan Customer Value Leadership Award

  6/29/2023

  Curia, a leading contract research, development and manufacturing organization, announced it has been awarded a Best Practices Customer Value Leadership Award in the CRDMO industry by Frost & Sullivan.

• Curia Expands Cell Line Development Offering with CHOZN PlatformCuria signs license agreement with MilliporeSigma to support production of proteins and antibodies

  6/20/2023

  Curia today announced it has signed a licensing agreement with MilliporeSigma, the North American Life Sciences Business of Merck KGaA, Darmstadt, Germany, that enables Curia and its clients to use the CHOZN® GS-/- cell line for production of therapeutic proteins and antibodies.

• Curia Collaborates with Corning to Advance Biopharmaceutical Continuous-Flow Development and Manufacturing Programs

  3/23/2023

  Curia, a leading contract research, development and manufacturing organization, announced a collaboration with Corning Incorporated to expand and accelerate continuous-flow development and manufacturing programs for the chemical and biopharmaceutical industries globally.

• Curia Appoints Philip Macnabb as Chief Executive Officer

  3/16/2023

  Curia today announced that Philip Macnabb has been appointed as chief executive officer, succeeding John Ratliff.

• Curia Appoints Niall Condon to Lead Manufacturing

  8/2/2022

  Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today announced the appointment of Niall Condon as president of its Manufacturing Division, with immediate effect.

• Curia and Replicate Bioscience Enter Strategic Collaboration to Create Groundbreaking Development Platform for Self-Replicating RNA (srRNA)

  6/9/2022

  Curia, formerly AMRI, a leading contract research, development and manufacturing organization, and Replicate Bioscience, a company pioneering ways to prevent drug resistance in cancer and to treat autoimmune and inflammatory disorders and other diseases using self-replicating RNA (srRNA), today announced that they will collaborate on a robust development platform for Replicate’s srRNA therapeutics.

• Curia Adopts the Berkeley Lights Platform to Expand its Antibody Discovery Capabilities

  6/6/2022

  Berkeley Lights, Inc., a leader in digital cell biology, and Curia, formerly AMRI, a leading contract research, development and manufacturing organization, announced Curia’s adoption of The Beacon® Optofluidic system and workflows from Berkeley Lights to accelerate and expand its antibody-based drug discovery capabilities.

• Curia Enters Cooperative Agreement with U.S. Government to Expand Sterile Fill-Finish Capability

  3/9/2022

  Curia announced a cooperative agreement with the BARDA, part of the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response, the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense and the U.S. Army Contracting Command to support the domestic production of injectable medicines.

• Integrity Bio and LakePharma Become Curia

  2/14/2022

  Curia, formerly AMRI, a leading contract research, development and manufacturing organization, announced that Integrity Bio and LakePharma, two companies that it acquired last year, have fully transitioned to the Curia brand.

• Curia Completes Acquisition of Integrity Bio

  8/4/2021

  Curia today announced it has completed the transaction to acquire Integrity Bio, Inc.

• AMRI Earns Spot on Forbes America’s Best Employers 2021 List

  3/9/2021

  Albany Molecular Research, Inc., a leading global provider of advanced contract research, development and manufacturing solutions, announced that the company is named on “America’s Best Mid-Sized Employers 2021” list published by Forbes.

• AMRI Wins 2021 CMO Leadership Awards

  2/1/2021

  Albany Molecular Research, Inc., a leading global provider of advanced contract research, development and manufacturing solutions, announced it has been recognized in the 2021 CMO Leadership Awards, presented by Outsourced Pharma and Life Science Leader.

• AMRI Included in BARDA CDMO Network in Support of COVID-19 Pandemic Response in the U.S.

  1/11/2021

  AMRI Included in BARDA CDMO Network in Support of COVID-19 Pandemic Response in the U.S.

• Albany Molecular Research Inc. (AMRI) Named Exclusive API Supplier for Recently Approved Acne Treatment

  10/30/2020

  Albany Molecular Research, Inc. (AMRI) today announced that it has been named as the exclusive supplier of the active pharmaceutical ingredient (API) in Cassiopea SpA’s (SIX: SKIN) recently approved acne treatment, Winlevi® (clascoterone) cream 1%. The United States Food and Drug Administration (FDA) approved Winlevi® (clascoterone) cream 1% in August 2020, marking a significant milestone in the treatment of acne vulga

• Albany Molecular Research Inc. (AMRI) to Present at Jefferies 2020 Virtual London Healthcare Conference

  10/14/2020

  Albany Molecular Research, Inc., ( AMRI ), a leading global provider of advanced contract research, development and manufacturing solutions, today announced that its CEO and CFO will present a corporate overview at the Jefferies 2020 Virtual London Healthcare Conference. The presentation, to be delivered by CEO John Ratliff and CFO Jason Knoblauch , will be recorded and made available on AMRI’s website. AMRI’s execu

• AMRI Selected to Support AstraZeneca in Delivery of COVID-19 Vaccine

  9/3/2020

  Albany Molecular Research, Inc. (AMRI), a leading global provider of advanced drug development and manufacturing solutions, today announced that it has signed a supply agreement with AstraZeneca to support the manufacture of AstraZeneca’s COVID-19 vaccine candidate AZD1222, intended to

• ViralClear Pharmaceuticals Partners With Albany Molecular Research Inc. (AMRI) on the Manufacture of Merimepodib Active Pharmaceutical Ingredient in Development for the Potential Treatment of COVID-19

  7/8/2020

  ViralClear Pharmaceuticals, Inc. (ViralClear), supported by Albany Molecular Research Inc. , (AMRI), a leading global contract research, development, and manufacturing organization (CDMO), is undertaking research to investigate the potential of merimepodib to fight SARS-CoV-2, the virus that causes COVID-19, either as a stand-alone treatment or in combination with other antiviral agents or immune modulators. “As p

• AMRI Leads the Industry in Highest Ranking from SafeBridge for Highly Potent Compound Safety

  4/23/2020

  Rensselaer, NY facility is the first and only facility to receive the top designation from SafeBridge Consultants

• John Ratliff Named CEO of Albany Molecular Research, Inc. (AMRI)

  12/2/2019

  Michael Mulhern Appointed Chairman of AMRI Board of Directors

• Prakash Pandian joins AMRI as Chief Information Officer

  6/11/2018

  AMRI announced the appointment of Prakash Pandian as chief information officer (CIO).